Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Collaborative program with the U.S. Department of Veterans Affairs aims to validate GDNF as a first-in-class biologic for obesi...
Hoth Therapeutics, Inc. (NASDAQ: HOTH) today highlighted FDA Orphan Drug Designation for HT-KIT and new preclinical data demons...
Under the new entitlement agreement, Hoth Therapeutics secures annual NVIDIA AI Enterprise Essentials licenses to support its G...
Presentation to highlight advancements in Hoth's clinical pipeline, includingHT-001 for cancer-therapy-induced rash and HT-...
MENIN inhibitors are a promising class of targeted oncology drugs in development for acute leukemias and certain solid tumors, ...
-SEC Filing
Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical innovator, today announced it has submitted its Clini...
